G protein-coupled receptor kinase 5

G protein-coupled receptor kinase 5
Name	G protein-coupled receptor kinase 5
Uniprot	P34947
Organism	Human

G protein-coupled receptor kinase 5 is a member of the G protein-coupled receptor kinase family involved in phosphorylation of activated seven-transmembrane receptors. It participates in receptor desensitization and signaling termination across diverse physiological pathways, influencing cardiovascular, neurological, and inflammatory responses. The kinase is studied in cellular, animal, and clinical contexts by researchers at institutions such as National Institutes of Health, Harvard University, Stanford University, and pharmaceutical companies including Pfizer and GlaxoSmithKline.

Function

GRK5 phosphorylates activated seven-transmembrane receptors to promote arrestin binding and receptor internalization, modulating signaling through pathways studied in work from Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, Massachusetts Institute of Technology, Johns Hopkins University, and University of Oxford. In cardiac myocytes, GRK5 influences adrenergic regulation linked to studies at Mayo Clinic, Cleveland Clinic, Imperial College London, University of Pennsylvania, and Duke University Hospital. Its role extends to neurobiology investigations by teams at Salk Institute, Columbia University, University College London, Weill Cornell Medicine, and University of California, San Francisco.

Structure and Mechanism

GRK5 comprises a central catalytic domain flanked by regulatory N-terminal and C-terminal regions; structural insights derive from crystallography and cryo-EM groups at European Molecular Biology Laboratory, Max Planck Society, Riken, Wellcome Trust Sanger Institute, and Protein Data Bank depositors. The mechanism of ATP-dependent phosphorylation resembles other AGC and CAMK family kinases characterized by researchers at ETH Zurich, Yale University, University of Cambridge, Rockefeller University, and Princeton University. Membrane targeting involves amphipathic helices and lipid interactions studied alongside membrane biology labs at University of California, San Diego, John Innes Centre, Karolinska Institutet, University of Toronto, and University of British Columbia.

Regulation and Post-translational Modifications

GRK5 activity is regulated by phosphorylation, acetylation, calmodulin binding, and lipidation; regulatory modifications were reported in collaborations among National Cancer Institute, European Molecular Biology Organization, Wellcome Trust, American Heart Association, and British Heart Foundation. Calmodulin-dependent regulation connects GRK5 to calcium signaling pathways examined by groups at University of Michigan, University of Chicago, Stanford University School of Medicine, Vanderbilt University, and University of Illinois at Chicago. Ubiquitination and proteasomal turnover studies have been pursued at Broad Institute, Scripps Research Institute, Mount Sinai Hospital, Columbia-Presbyterian Medical Center, and University of Texas Southwestern Medical Center.

Tissue Distribution and Expression

Expression profiling shows high GRK5 abundance in heart, brain, lung, and immune tissues, with transcriptomic datasets generated by consortia including ENCODE Project, GTEx Consortium, Human Protein Atlas, 1000 Genomes Project, and International HapMap Project. Developmental and cell-type specific expression has been analyzed by teams at European Bioinformatics Institute, Institut Pasteur, UCL Great Ormond Street Institute of Child Health, Roche, and Novartis. Comparative expression across species has been reported in studies from University of Cambridge Zoology Department, Max Planck Institute for Evolutionary Anthropology, Smithsonian Institution, Australian National University, and University of Auckland.

Clinical Significance and Disease Associations

Variants and dysregulation of GRK5 associate with cardiovascular disease, heart failure, hypertrophy, and response to beta-blocker therapy; clinical trials and translational research have involved Food and Drug Administration, European Medicines Agency, American College of Cardiology, European Society of Cardiology, and British Heart Foundation. Neurodegenerative and psychiatric links—including Alzheimer's disease and mood disorders—have been investigated by consortia and centers such as Alzheimer's Association, National Institute of Mental Health, Karolinska University Hospital, Mayo Clinic Alzheimer's Disease Research Center, and Mount Sinai School of Medicine. Cancer associations and prognostic studies have been reported from Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, University of Texas MD Anderson Cancer Center, Fred Hutchinson Cancer Center, and Johns Hopkins Kimmel Cancer Center.

Interactions and Substrates

GRK5 interacts with G protein-coupled receptors including beta-adrenergic receptors and muscarinic receptors, and with regulatory proteins such as arrestins, calmodulin, and phospholipids; biochemical interaction mapping has been performed by labs at Cold Spring Harbor Laboratory, Scripps Research Institute, Howard Hughes Medical Institute, Max Planck Institute of Biochemistry, and University of Oxford. Substrate identification platforms used by groups at EMBL-EBI, ProteomeXchange, Wellcome Trust Sanger Institute, Broad Institute, and Yale Center for Proteomics expanded the substrate list to signaling and structural proteins.

Model Organisms and Experimental Studies

Genetic knockout and transgenic mouse models of GRK5 have been developed and characterized at institutions including Jackson Laboratory, European Molecular Biology Laboratory Mouse Biology Unit, Harvard Medical School, University of California, Los Angeles, and Cold Spring Harbor Laboratory, informing phenotypes in cardiac, neurological, and immune systems. Zebrafish, Drosophila, and rat models studied at Ecole Polytechnique Fédérale de Lausanne, University of Basel, Max Planck Institute for Developmental Biology, Hôpital Necker-Enfants Malades, and University of Queensland provided developmental and pharmacological insights. High-throughput screens and chemical biology studies by Broad Institute, Novartis Institutes for BioMedical Research, GlaxoSmithKline, Pfizer and academic partners identified modulators and tool compounds.

Category:Protein kinases